Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07063693 · ClinicalTrials.gov registry record · Phase 1
ABY-029 Glioma Trial
A Phase 1 study of Intracranial Tumor, sponsored by Dartmouth-Hitchcock Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT07063693 is a Phase 1 study of Intracranial Tumor that is actively recruiting participants, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 33 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07063693, a Phase 1 study of Intracranial Tumor, is actively recruiting participants, sponsored by Dartmouth-Hitchcock Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purposes of the research trial are to study the safety of ABY-029 and to understand how much of the drug is needed to reach brain tumors so it can be visualized best by surgeons. Investigators will do this by comparing two groups of participants that receive different, very small amounts of ABY-029. Investigators will use an imaging system during surgery to record the amount of ABY-029 in the participant's tumor and in the surrounding tissue.
Conditions Studied
Interventions
- DRUG ABY-029
Study Locations (1)
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2026-02-17 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07063693
The ClinicalTrials.gov registry entry for NCT07063693 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intracranial Tumor appearing as the primary indexed condition, and to 1 intervention - of which ABY-029 is the first listed.
NCT07063693 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.
Frequently Asked Questions
What is clinical trial NCT07063693 about?
NCT07063693 is a clinical study titled "ABY-029 Glioma Trial". The purposes of the research trial are to study the safety of ABY-029 and to understand how much of the drug is needed to reach brain tumors so it can be visualized best by surgeons. Investigators will do this by comparing two groups of participants that receive different, very small amounts of ABY-...
What is the current status of trial NCT07063693?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2026-02-17. Estimated completion is 2028-12-31.
What conditions does trial NCT07063693 study?
This clinical trial studies the following conditions: Intracranial Tumor.
What interventions are being tested in trial NCT07063693?
The interventions under investigation include: ABY-029 (DRUG).
Who is sponsoring clinical trial NCT07063693?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07063693 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.